Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Research Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (6990.HK) on Bullrun: market cap HKD 108.04B, P/E 627.8. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker6990.HK
- ExchangeHK
- CountryChina
- SectorHealthcare
- IndustryBiotechnology
- CurrencyHKD
- Market capHKD 108.04B
- P/E627.8
- Financial periodFY2025
- RevenueCNY 2.06B
- Revenue growth6.5%
- Net income-CNY 381.97M
- Free cash flow-CNY 306.55M
- Gross margin71.9%
Valuation Snapshot
latest market cap is HKD 108.04B; P/E is 627.8.
Peer valuation comparison
Latest P/E is 627.78x versus a Healthcare sector median of 21.69x (2794.0% above).
Latest P/E is 627.78x versus a China median of 16.26x (3760.1% above).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | CNY 2.06B | -CNY 381.97M | -CNY 306.55M | 71.9% | -1.66 | CNY 3.33B | CNY 88.44M | CNY 4.87B |
| FY2024 | CNY 1.93B | -CNY 266.77M | -CNY 510.89M | 65.9% | -1.2 | CNY 1.34B | CNY 126.75M | CNY 3.31B |
| FY2023 | CNY 1.54B | -CNY 574.13M | -CNY 22.69M | 49.3% | -2.84 | CNY 1.57B | CNY 59.92M | CNY 2.33B |
| FY2022 | CNY 803.93M | -CNY 616.10M | -CNY 309.84M | 65.6% | -2.54 | CNY 119.22M | CNY 3.01B | -CNY 3.23B |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | HKD 108.04B | 627.8 | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 HKD.
About Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., a biopharmaceutical company, engages in the research and development, manufacturing, and commercialization of novel drugs in oncology, immunology, metabolism, and other therapeutic areas in the People's Republic of China and internationally. The company's product pipeline includes Sac-TMT, a novel TROP2 ADC positioned as a monotherapy and part of combination therapies for treating various advanced solid tumors;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.'s market cap?
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.'s market capitalization is HKD 108.04B.
What is Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.'s P/E ratio?
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.'s price-to-earnings (P/E) ratio is 627.8.
What does Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. do?
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., a biopharmaceutical company, engages in the research and development, manufacturing, and commercialization of novel drugs in oncology, immunology, metabolism, and other therapeutic areas in the People's Republic of China and internationally.